NCT07431216 2026-03-30A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First ProgressionStarlight Therapeutics Inc.Phase 1/2 Not yet recruiting68 enrolled